DOCSLIB.ORG

Imaging Glutamate in Schizophrenia: Review of Findings and Implications for Drug Discovery

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Imaging Glutamate in Schizophrenia: Review of Findings and Implications for Drug Discovery Molecular Psychiatry (2014) 19, 20–29 & 2014 Macmillan Publishers Limited All rights reserved 1359-4184/14 www.nature.com/mp REVIEW Imaging glutamate in schizophrenia: review of findings and implications for drug discovery EMP Poels1,2, LS Kegeles1,2, JT Kantrowitz1,2, M Slifstein1,2, DC Javitt1,2, JA Lieberman1,2, A Abi-Dargham1,2,3 and RR Girgis1,2 Currently, all treatments for schizophrenia (SCZ) function primarily by blocking D2-type dopamine receptors. Given the limitations of these medications, substantial efforts have been made to identify alternative neurochemical targets for treatment development in SCZ. One such target is brain glutamate. The objective of this article is to review and synthesize the proton magnetic resonance spectroscopy (1H MRS) and positron emission tomography (PET)/single-photon emission computed tomography (SPECT) investigations that have examined glutamatergic indices in SCZ, including those of modulatory compounds such as glutathione (GSH) and glycine, as well as data from ketamine challenge studies. The reviewed 1H MRS and PET/SPECT studies support the theory of hypofunction of the N-methyl-D-aspartate receptor (NMDAR) in SCZ, as well as the convergence between the dopamine and glutamate models of SCZ. We also review several advances in MRS and PET technologies that have opened the door for new opportunities to investigate the glutamate system in SCZ and discuss some ways in which these imaging tools can be used to facilitate a greater understanding of the glutamate system in SCZ and the successful and efficient development of new glutamate-based treatments for SCZ. Molecular Psychiatry (2014) 19, 20–29; doi:10.1038/mp.2013.136; published online 29 October 2013 Keywords: glutamate; glutathione; magnetic resonance spectroscopy (MRS); NMDA; positron emission tomography (PET); schizophrenia INTRODUCTION emission tomography (PET)/single-photon emission computed At present, the antipsychotics (typical or atypical) are the only tomography (SPECT) investigations that have examined glutama- approved treatments for schizophrenia (SCZ). In many patients, tergic indices in SCZ, including those of modulatory compounds 1 psychotic symptoms are only partially responsive or completely such as glutathione (GSH) and glycine. We will also review H MRS/ unresponsive to antipsychotic drugs,1 and there are currently no PET/SPECT work that has been performed using the ketamine agents with proven efficacy for negative symptoms or persistent challenge model in healthy subjects and discuss their patho- neurocognitive dysfunction. Even for subjects who respond well physiological implications. Preclinical and clinical evidence sup- to treatments, existing medications are associated with significant porting a role for each particular component of the glutamatergic cognitive, motoric or metabolic side effects that limit compliance. system in SCZ will be reviewed, followed by summaries of the 1 Thus, newer treatments for SCZ are desperately required. relevant H MRS and/or PET/SPECT literature. We will conclude All current treatments for SCZ function primarily by blocking D2- with a discussion of how these neurochemical findings inform the type dopamine receptors.2 Alternative neurochemical theories glutamate hypothesis of SCZ and can enhance drug development focus on disturbances in brain glutamatergic pathways, including of glutamatergic agents in SCZ. impairments in signaling at synaptic N-methyl-D-aspartate (NMDA)-type glutamate receptors (NMDARs; Figure 1).3,4 Approaches for normalization of glutamatergic function are GLUTAMATE AND THE NMDA RECEPTOR currently under development. To date, promising results have Background: evidence for NMDA receptor dysfunction in SCZ been obtained with compounds such as glycine, D-serine, In initial studies with phencyclidine and ketamine in the early sarcosine5 and glycine transport inhibitors6 that target the 1960s, it was noted that both agents produced positive, negative glycine site of the NMDAR, and with N-acetylcysteine (NAC), a and cognitive symptoms of SCZ.8,9 These compounds induce precursor compound for the amino acid cysteine in brain.5 symptoms by blocking neurotransmission at the NMDAR, sug- However, the slow rate of therapeutic development has led a gesting an alternative model for pathogenesis in SCZ. Sympto- group of leading experts from academia, government and matic effects of NMDAR blockade were better classified starting in PHARMA7 to conclude that effectively translating findings from the early 1990s in a series of ketamine challenge studies genetics and basic science into therapies will require the conducted in both normal volunteers and SCZ patients.10–13 In development of robust biomarkers and assessment of target normal volunteers, positive, negative and cognitive symptoms engagement of experimental agents.7 were observed in similar proportions as in SCZ. NMDAR blockade The objective of this article is to review and synthesize the also reproduces both the severity and type of thought disorder proton magnetic resonance spectroscopy (1H MRS) and positron seen in SCZ with both, for example, being associated with high 1Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA; 2New York State Psychiatric Institute, New York, NY, USA and 3Department of Radiology, Columbia University College of Physicians and Surgeons, New York, NY, USA. Correspondence: Dr RR Girgis, Department of Psychiatry, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 31, New York, NY 10032, USA. E-mail: [email protected] Received 23 March 2013; revised 25 August 2013; accepted 9 September 2013; published online 29 October 2013 Glutamate imaging in schizophrenia EMP Poels et al 21 levels of poverty of speech, circumstantiality and loss of goal, and relatively low levels of distractive or stilted speech or parapha- sias.11 These data and others suggest that reduction in NMDA functioning within the brain could serve as a single unifying feature to account for the otherwise complex pattern of deficits observed in SCZ (see review in Kantrowitz and Javitt4). The development of the glutamate hypothesis of SCZ, initially based in large part on the effects of phencyclidine, closely resembles the initial development of the dopamine hypothesis of SCZ, which was based in large part on observations of the psychotogenic effects of stimulant medications.14 PET and SPECT later supported this hypothesis by indicating increased dopamine synthesis,15–17 greater striatal amphetamine-stimulated dopamine release that is related to positive symptoms18–20 and increased baseline occupancy of striatal dopamine D2 receptors by dopa- mine that also predicts the response of positive symptoms to treatment with antipsychotic agents.21 The negative symptoms and cognitive deficits of SCZ are thought to be related, at least in part, to a cortical dopamine deficit, as originally proposed Figure 1. Schematic diagram of N-methyl-D-aspartate (NMDA) by Weinberger22 and Davis et al.23 based on preclinical and receptor showing D-serine and glutathione/redox-sensitive modula- tory sites (reprinted from Javitt Javitt DC, Int Rev Neurobiol, volume other indirect data. PET studies of cortical dopamine D1 24–27 78, Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspar- receptors reported inconsistent results, and more direct tate receptors, and dopamine-glutamate interactions, pages 69–108, examination of dopaminergic transmission in the cortex is Copyright 2007 with permission from Elsevier). currently underway. A point of convergence of the dopamine and NMDA models is In summary, PET and SPECT studies testing the effects of NMDA at the level of local regulation of presynaptic dopamine release. blockade on dopaminergic indices in healthy subjects using Within striatum and frontal cortex, presynaptic dopamine release ketamine alone found mixed results in striatum,29–33,35 but is under control of intrinsic inhibitory GABAergic neurons that, in significant effects in cortex, consistent with prior rodent data.37 turn, are activated by NMDAR. In striatum, regulation of dopamine However, strikingly similar results for amphetamine-induced release appears to be modulated by GABAB receptors localized to dopamine release in individuals with SCZ and healthy subjects presynaptic dopamine terminals. GABA release, in turn, is given acute ketamine35 provide initial support for the glutamate/ modulated by NMDAR located on GABA interneurons, with 28 NMDA hypothesis of SCZ. Nevertheless, direct, in vivo measure- stimulation leading to increased GABA release. Therefore, ments of glutamatergic indices are necessary to translate some of the initial imaging studies of the glutamatergic system preclinical and clinical findings into effective therapies. Although sought to further validate the glutamate/NMDA model of SCZ by the development of PET and SPECT imaging of the glutamate examining the effects of ketamine on dopamine transmission and system has lagged behind that of the dopamine system, MRS receptors in healthy control subjects. technologies have effectively been utilized to measure gluta- matergic indices in vivo. Glutamate and dopamine PET/SPECT 1 Several studies used the D2/D3 receptor PET/SPECT ligands Glutamatergic H MRS [11C]raclopride and [123]iodobenzamide ([123]IBZM) to measure Several studies have compared glutamatergic indices—namely the effects of ketamine infusion in healthy control subjects on glutamate (Glu), glutamine (Gln) or Glu þ Gln (Glx)—in the brains 1 D2/D3 receptor
Load more

Recommended publications
  • Mglu2 Receptor Agonism, but Not Positive Allosteric Modulation, Elicits Rapid Tolerance Towards Their Primary Efficacy on Sleep Measures in Rats
    RESEARCH ARTICLE mGlu2 Receptor Agonism, but Not Positive Allosteric Modulation, Elicits Rapid Tolerance towards Their Primary Efficacy on Sleep Measures in Rats Abdallah Ahnaou1*, Hilde Lavreysen1, Gary Tresadern2, Jose M. Cid2, Wilhelmus H. Drinkenburg1 1 Dept. of Neuroscience, Janssen Research & Development, A Division of Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340, Beerse, Belgium, 2 Neuroscience Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., Jarama 75, Polígono Industrial, 45007, Toledo, Spain * [email protected] Abstract OPEN ACCESS G-protein-coupled receptor (GPCR) agonists are known to induce both cellular adaptations Citation: Ahnaou A, Lavreysen H, Tresadern G, Cid resulting in tolerance to therapeutic effects and withdrawal symptoms upon treatment dis- JM, Drinkenburg WH (2015) mGlu2 Receptor continuation. Glutamate neurotransmission is an integral part of sleep-wake mechanisms, Agonism, but Not Positive Allosteric Modulation, Elicits Rapid Tolerance towards Their Primary which processes have translational relevance for central activity and target engagement. Efficacy on Sleep Measures in Rats. PLoS ONE 10 Here, we investigated the efficacy and tolerance potential of the metabotropic glutamate (12): e0144017. doi:10.1371/journal.pone.0144017 receptors (mGluR2/3) agonist LY354740 versus mGluR2 positive allosteric modulator Editor: James Porter, University of North Dakota, (PAM) JNJ-42153605 on sleep-wake organisation in rats. In vitro, the selectivity and UNITED STATES potency of JNJ-42153605 were characterized. In vivo, effects on sleep measures were Received: July 12, 2015 investigated in rats after once daily oral repeated treatment for 7 days, withdrawal and con- Accepted: November 12, 2015 secutive re-administration of LY354740 (1–10 mg/kg) and JNJ-42153605 (3–30 mg/kg).
    [Show full text]
  • Selective Blockade of the Metabotropic Glutamate Receptor Mglur5 Protects Mouse Livers in in Vitro and Ex Vivo Models of Ischemia Reperfusion Injury
    International Journal of Molecular Sciences Article Selective Blockade of the Metabotropic Glutamate Receptor mGluR5 Protects Mouse Livers in In Vitro and Ex Vivo Models of Ischemia Reperfusion Injury Andrea Ferrigno 1,* ID , Clarissa Berardo 1, Laura Giuseppina Di Pasqua 1, Veronica Siciliano 1, Plinio Richelmi 1, Ferdinando Nicoletti 2,3 and Mariapia Vairetti 1 ID 1 Department of Internal Medicine and Therapeutics, Cellular and Molecular Pharmacology and Toxicology Unit, University of Pavia, 27100 Pavia, Italy; [email protected] (C.B.); [email protected] (L.G.D.P.); [email protected] (V.S.); [email protected] (P.R.); [email protected] (M.V.) 2 Department of Physiology and Pharmacology, Sapienza University, 00185 Roma, Italy; [email protected] 3 I.R.C.C.S. Neuromed, 86077 Pozzilli, Italy * Correspondence: [email protected]; Tel.: +39-0382-986451 Received: 20 November 2017; Accepted: 22 January 2018; Published: 23 January 2018 Abstract: 2-Methyl-6-(phenylethynyl)pyridine (MPEP), a negative allosteric modulator of the metabotropic glutamate receptor (mGluR) 5, protects hepatocytes from ischemic injury. In astrocytes and microglia, MPEP depletes ATP. These findings seem to be self-contradictory, since ATP depletion is a fundamental stressor in ischemia. This study attempted to reconstruct the mechanism of MPEP-mediated ATP depletion and the consequences of ATP depletion on protection against ischemic injury. We compared the effects of MPEP and other mGluR5 negative modulators on ATP concentration when measured in rat hepatocytes and acellular solutions. We also evaluated the effects of mGluR5 blockade on viability in rat hepatocytes exposed to hypoxia. Furthermore, we studied the effects of MPEP treatment on mouse livers subjected to cold ischemia and warm ischemia reperfusion.
    [Show full text]
  • Metabotropic Glutamate Receptors
    mGluR Metabotropic glutamate receptors mGluR (metabotropic glutamate receptor) is a type of glutamate receptor that are active through an indirect metabotropic process. They are members of thegroup C family of G-protein-coupled receptors, or GPCRs. Like all glutamate receptors, mGluRs bind with glutamate, an amino acid that functions as an excitatoryneurotransmitter. The mGluRs perform a variety of functions in the central and peripheral nervous systems: mGluRs are involved in learning, memory, anxiety, and the perception of pain. mGluRs are found in pre- and postsynaptic neurons in synapses of the hippocampus, cerebellum, and the cerebral cortex, as well as other parts of the brain and in peripheral tissues. Eight different types of mGluRs, labeled mGluR1 to mGluR8, are divided into groups I, II, and III. Receptor types are grouped based on receptor structure and physiological activity. www.MedChemExpress.com 1 mGluR Agonists, Antagonists, Inhibitors, Modulators & Activators (-)-Camphoric acid (1R,2S)-VU0155041 Cat. No.: HY-122808 Cat. No.: HY-14417A (-)-Camphoric acid is the less active enantiomer (1R,2S)-VU0155041, Cis regioisomer of VU0155041, is of Camphoric acid. Camphoric acid stimulates a partial mGluR4 agonist with an EC50 of 2.35 osteoblast differentiation and induces μM. glutamate receptor expression. Camphoric acid also significantly induced the activation of NF-κB and AP-1. Purity: ≥98.0% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg (2R,4R)-APDC (R)-ADX-47273 Cat. No.: HY-102091 Cat. No.: HY-13058B (2R,4R)-APDC is a selective group II metabotropic (R)-ADX-47273 is a potent mGluR5 positive glutamate receptors (mGluRs) agonist.
    [Show full text]
  • Advancing Quantitative Structure Activity Relationship Strategies in Ligand-Based Computer-Aided Drug Design
    ADVANCING QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP STRATEGIES IN LIGAND-BASED COMPUTER-AIDED DRUG DESIGN By Mariusz Butkiewicz Dissertation Submitted to the Faculty of the Graduate School of Vanderbilt University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY In Chemistry August, 2014 Nashville, Tennessee Approved: Jens Meiler, Ph.D. Brian O. Bachmann, Ph.D. David W. Wright, Ph.D. Clare M. McCabe, Ph.D. Copyright © 2014 by Mariusz Butkiewicz All Rights Reserved ii DEDICATION To my parents, my sister, and Nicole. iii ACKNOWLEDGEMENTS Over the past years, I have received support and encouragement from a great number of individuals to whom I am very grateful. I would like to express my deepest and sincere gratitude to my advisor, Dr. Jens Meiler. Coming to Nashville and joining the Meiler laboratory to start my graduate studies has been a tremendous opportunity and extraordinary experience in my life. Jens was an excellent mentor and supported me on each step in my graduate career. His guidance taught me how to approach scientific problems, how to ask-the right scientific questions, and how to write and present scientific work. Jens found the right balance between encouraging my own scientific explorations and providing invaluable guidance and help. I would like to thank Dr. Meiler for making the past several years such a pleasant academic experience. The members of my dissertation committee, Dr. David Wright, Dr. Brian Bachmann, and Dr. Clare McCabe, were a great source of support and guidance for my graduate work. Their insightful comments and constructive criticism gave appreciated impulses to my research.
    [Show full text]
  • The G Protein-Coupled Glutamate Receptors As Novel Molecular Targets in Schizophrenia Treatment— a Narrative Review
    Journal of Clinical Medicine Review The G Protein-Coupled Glutamate Receptors as Novel Molecular Targets in Schizophrenia Treatment— A Narrative Review Waldemar Kryszkowski 1 and Tomasz Boczek 2,* 1 General Psychiatric Ward, Babinski Memorial Hospital in Lodz, 91229 Lodz, Poland; [email protected] 2 Department of Molecular Neurochemistry, Medical University of Lodz, 92215 Lodz, Poland * Correspondence: [email protected] Abstract: Schizophrenia is a severe neuropsychiatric disease with an unknown etiology. The research into the neurobiology of this disease led to several models aimed at explaining the link between perturbations in brain function and the manifestation of psychotic symptoms. The glutamatergic hypothesis postulates that disrupted glutamate neurotransmission may mediate cognitive and psychosocial impairments by affecting the connections between the cortex and the thalamus. In this regard, the greatest attention has been given to ionotropic NMDA receptor hypofunction. However, converging data indicates metabotropic glutamate receptors as crucial for cognitive and psychomotor function. The distribution of these receptors in the brain regions related to schizophrenia and their regulatory role in glutamate release make them promising molecular targets for novel antipsychotics. This article reviews the progress in the research on the role of metabotropic glutamate receptors in schizophrenia etiopathology. Citation: Kryszkowski, W.; Boczek, T. The G Protein-Coupled Glutamate Keywords: schizophrenia; metabotropic glutamate receptors; positive allosteric modulators; negative Receptors as Novel Molecular Targets allosteric modulators; drug development; animal models of schizophrenia; clinical trials in Schizophrenia Treatment—A Narrative Review. J. Clin. Med. 2021, 10, 1475. https://doi.org/10.3390/ jcm10071475 1. Introduction Academic Editors: Andreas Reif, Schizophrenia is a common debilitating disease affecting about 0.3–1% of the human Blazej Misiak and Jerzy Samochowiec population worldwide [1].
    [Show full text]
  • Dynamic L-Glutamate Signaling in the Prefrontal Cortex and the Effects of Methylphenidate Treatment
    University of Kentucky UKnowledge Theses and Dissertations--Neuroscience Neuroscience 2012 DYNAMIC L-GLUTAMATE SIGNALING IN THE PREFRONTAL CORTEX AND THE EFFECTS OF METHYLPHENIDATE TREATMENT Catherine Elizabeth Mattinson University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Mattinson, Catherine Elizabeth, "DYNAMIC L-GLUTAMATE SIGNALING IN THE PREFRONTAL CORTEX AND THE EFFECTS OF METHYLPHENIDATE TREATMENT" (2012). Theses and Dissertations--Neuroscience. 4. https://uknowledge.uky.edu/neurobio_etds/4 This Doctoral Dissertation is brought to you for free and open access by the Neuroscience at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Neuroscience by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained and attached hereto needed written permission statements(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine). I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known. I agree that the document mentioned above may be made available immediately for worldwide access unless a preapproved embargo applies.
    [Show full text]
  • The Effect of Intrahippocampal Injection of Group II and III Metobotropic Glutamate Receptor Agonists on Anxiety; the Role of Neuropeptide Y
    Neuropsychopharmacology (2007) 32, 1242–1250 & 2007 Nature Publishing Group All rights reserved 0893-133X/07 $30.00 www.neuropsychopharmacology.org The Effect of Intrahippocampal Injection of Group II and III Metobotropic Glutamate Receptor Agonists on Anxiety; the Role of Neuropeptide Y ´ ,1 1 1 1 Maria Smiałowska* , Joanna M Wieron´ska , Helena Domin and Barbara Zie˛ba 1Department of Neurobiology, Institute of Pharmacology, Polish Academy of Sciences, Krako´w, Poland Earlier studies conducted by our group and by other authors indicated that metabotropic glutamatergic receptor (mGluR) ligands might have anxiolytic activity and that amygdalar neuropeptide Y (NPY) neurons were engaged in that effect. Apart from the amygdala, the hippocampus, another limbic structure, also seems to be engaged in regulation of anxiety. It is rich in mGluRs and contains numerous NPY interneurons. In the present study, we investigated the anxiolytic activity of group II and III mGluR agonists after injection into the hippocampus, and attempted to establish whether hippocampal NPY neurons and receptors were engaged in the observed effects. Male Wistar rats were bilaterally microinjected with the group II mGluR agonist (2S,10S,20S)-2-(carboxycyclopropyl)glycine (L-CCG-I), group III mGluR agonist O-Phospho-L-serine (L-SOP), NPY, the Y1 receptor antagonist BIBO 3304, and the Y2 receptor antagonist BIIE 0246 into the CA1 or dentate area (DG). The effect of those compounds on anxiety was tested in the elevated plus-maze. Moreover, the effects of L-CCG-I and L-SOP on the expression of NPYmRNA in the hippocampus were studied using in situ hybridization method. It was found that a significant anxiolytic effect was induced by L-SOP injection into the CA1 region or by L-CCG-I injection into the DG.
    [Show full text]
  • Acamprosate in the Treatment of Binge Eating Disorder: a Placebo-Controlled Trial
    CE ACTIVITY Acamprosate in the Treatment of Binge Eating Disorder: A Placebo-Controlled Trial Susan L. McElroy, MD1* ABSTRACT obsessive-compulsiveness of binge eat- 1 Objective: To assess preliminarily the ing, food craving, and quality of life. Anna I. Guerdjikova, PhD effectiveness of acamprosate in binge Among completers, weight and BMI 1 Erin L. Winstanley, PhD eating disorder (BED). decreased slightly in the acamprosate 1 group but increased in the placebo Anne M. O’Melia, MD Method: In this 10-week, randomized, 1 group. Nicole Mori, CNP placebo-controlled, flexible dose trial, 40 1 Jessica McCoy, BA outpatients with BED received acampro- Discussion: Although acamprosate did Paul E. Keck Jr., MD1 sate (N 5 20) or placebo (N 5 20). The not separate from placebo on any out- James I. Hudson, MD, ScD2 primary outcome measure was binge eat- come variable in the longitudinal analy- ing episode frequency. sis, results of the endpoint and completer analyses suggest the drug may have Results: While acamprosate was not some utility in BED. VC 2010 by Wiley associated with a significantly greater Periodicals, Inc. rate of reduction in binge eating episode frequency or any other measure in the Keywords: acamprosate; binge eating primary longitudinal analysis, in the end- disorder; obesity; glutamate point analysis it was associated with stat- istically significant improvements in binge day frequency and measures of (Int J Eat Disord 2011; 44:81–90) Introduction The treatment of BED remains a challenge.5 Cogni- tive behavioral and interpersonal therapies and selec- Binge eating disorder (BED), characterized by recur- tive serotonin-reuptake inhibitor (SSRI) antidepres- rent binge-eating episodes without inappropriate sants are effective for reducing binge eating, but usu- 1 compensatory weight loss behaviors, is an impor- ally are not associated with clinically significant tant public health problem.
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • Structural Studies of the Interaction Between Mglu5 And
    STRUCTURAL STUDIES OF THE INTERACTION BETWEEN MGLU5 AND ALLOSTERIC MODULATORS By Elizabeth Dong Nguyen Dissertation Submitted to the Faculty of the Graduate School of Vanderbilt University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in Chemical and Physical Biology August, 2013 Nashville, Tennessee Approved: Professor Walter J. Chazin Professor P. Jeffrey Conn Professor Terry P. Lybrand Professor David L. Tabb Copyright © 2013 by Elizabeth Dong Nguyen All Rights Reserved ACKNOWLEDGEMENTS The work presented here was made possible by Public Health Service award T32 GM07347 from the National Institute of General Medical Studies for the Vanderbilt Medical-Scientist Training Program (MSTP), the Paul Calabresi Medical Student Research Fellowship from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation and a Deutscher Akademischer Austausch Dienst (DAAD) research grant from the German Academic Exchange Service. Computational resources were provided by the Advanced Computing Center for Research and Education and the Center for Structural Biology at Vanderbilt University. I would like to thank my advisor, Dr. Jens Meiler, who fostered in me the desire to pursue research as a summer undergraduate student and continued to support, guide and mentor me through my graduate studies. His excitement for science is infectious and has inspired my own ambitions to spread the passion of science to others. I would like to thank other faculty members who aided in my scientific growth while at Vanderbilt University, particularly my committee members: Dr. Walter Chazin, Dr. Jeff Conn, Dr. Terry Lybrand and Dr. David Tabb. They have continually provided guidance and encouragement for my research progress and career development.
    [Show full text]
  • Addiction Research Tools
    Addiction Research Tools Cayman offers a wide range of products to study targeted brain circuits mediating the behavioral effects of drugs of abuse. We also offer over 2,000 high-quality analytical standards that have been synthesized using a range of analytical techniques to verify identity, purity, and other relevant characteristics. Whether you are looking to quickly identify or quantify drugs of abuse via mass spec or understand their physiological and toxicological properties, Cayman has the right tools to help make your research possible. DopamineDopamine transportertransporters s DopamineDopamine Drugs Drugs DopamineDopamine receptorresceptors Drugs of Abuse Amphetamines and Other Stimulants Benzodiazepines Item No. Product Name Item No. Product Name 15650 D-Amphetamine (hydrochloride) (exempt preparation) 15287 α-hydroxy Alprazolam 10488 Bupropion (hydrochloride) 14263 Clonazepam 15655 (–)-(S)-Cathinone (hydrochloride) (exempt preparation) 18173 Clonazolam 22165 Cocaine (hydrochloride) 15554 Diclazepam 11159 Dimethocaine (hydrochloride) 15889 Estazolam 11630 Ketamine (hydrochloride) 24481 Flualprazolam 13971 3,4-MDMA (hydrochloride) 11449 Ketazolam 15657 Mephedrone (hydrochloride) (exempt preparation) 15891 Lorazepam 15656 Methcathinone (hydrochloride) (exempt preparation) 16193 Midazolam 14276 PCP (hydrochloride) 22577 Triazolam Over 650 amphetamine and other stimulant standards available online Over 100 benzodiazepine standards available online Addiction Research Products are available in BULK quantities to qualified institutions
    [Show full text]
  • Hayward Et Al, 2016
    Pharmacology & Therapeutics 158 (2016) 41–51 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate Editor: F. Tarazi Low attentive and high impulsive rats: A translational animal model of ADHD and disorders of attention and impulse control Andrew Hayward a,⁎, Anneka Tomlinson b, Joanna C. Neill a,⁎ a Manchester Pharmacy School, University of Manchester, Manchester M13 9PT, UK b Green Templeton College, University of Oxford, Oxford OX2 6HG, UK article info abstract Available online 23 November 2015 Many human conditions such as attention deficit hyperactivity disorder (ADHD), schizophrenia and drug abuse are characterised by deficits in attention and impulse control. Carefully validated animal models are required to Keywords: enhance our understanding of the pathophysiology of these disorders, enabling development of improved phar- Animal model macotherapy. Recent models have attempted to recreate the psychopathology of these conditions using chemical ADHD lesions or genetic manipulations. In a diverse population, where the aetiology is not fully understood and is 5C-SRTT multifactorial, these methods are restricted in their ability to identify novel targets for drug discovery. Two 5C-CPT tasks of visual attention and impulsive action typically used in rodents and based on the human continuous High Performance Low Performance performance task (CPT) include, the well-established 5 choice serial reaction time task (5C-SRTT) and the more recently validated, 5 choice continuous performance task (5C-CPT) which provides enhanced translational value. We suggest that separating animals by behavioural performance into high and low attentive and impulsivity cohorts using established parameters in these tasks offers a model with enhanced translational value.
    [Show full text]